Xeris Biopharma Q4 2023 Earnings Report
Key Takeaways
Xeris Biopharma reported a strong Q4 2023 with a 34% increase in total revenue, reaching over $44 million, and achieved cash flow positive status with over $6 million. The company ended the year with over $72 million in cash, cash equivalents, and short-term investments. They also refinanced their Hayfin term loan and entered into a worldwide license agreement for XeriJect® formulation of teprotumumab.
Total revenue reached over $44 million, a 34% increase compared to the same period last year.
Ended the year with over $72 million in cash, cash equivalents, and short-term investments.
Achieved cash flow positive status with over $6 million in the fourth quarter.
Entered into a worldwide license agreement for XeriJect® formulation of teprotumumab.
Xeris Biopharma
Xeris Biopharma
Xeris Biopharma Revenue by Segment
Forward Guidance
Xeris Biopharma anticipates total net revenue between $170 million and $200 million and year-end cash, cash equivalents, and short-term investments between $55 million and $75 million for the full year 2024.
Positive Outlook
- Expects to grow total revenue in the range of $170 million to $200 million.
- Double-digit revenue growth.
- Recent debt refinancing.
- Continued disciplined cash management.
- Expects to end 2024 with a very healthy cash position of $55 million to $75 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income